PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss?
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40065397.
- Also identified by DOI 10.1097/RLU.0000000000005816.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177 Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177 Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177 Lu-PSMA-617 was explored using dosimetric analysis.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Glutamate Carboxypeptidase II
- Antigens, Surface
- Heterocyclic Compounds, 1-Ring
- Dipeptides
- Theranostic Nanomedicine